Conor McNamara
Stock Analyst at RBC Capital
(0.88)
# 3,794
Out of 4,893 analysts
124
Total ratings
24.18%
Success rate
-18.34%
Average return
Main Sectors:
Stocks Rated by Conor McNamara
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
TECH Bio-Techne | Maintains: Sector Perform | $72 → $63 | $54.41 | +15.79% | 9 | May 8, 2025 | |
HOLX Hologic | Maintains: Sector Perform | $75 → $70 | $66.85 | +4.71% | 11 | May 2, 2025 | |
BIO Bio-Rad Laboratories | Maintains: Outperform | $409 → $392 | $259.88 | +50.84% | 11 | May 2, 2025 | |
BIO.B Bio-Rad Laboratories | Maintains: Outperform | $409 → $392 | $261.85 | +49.70% | 11 | May 2, 2025 | |
RGEN Repligen | Maintains: Outperform | $202 → $189 | $134.00 | +41.04% | 11 | Apr 30, 2025 | |
AVTR Avantor | Maintains: Outperform | $24 → $20 | $13.70 | +45.99% | 7 | Apr 28, 2025 | |
TMO Thermo Fisher Scientific | Maintains: Outperform | $651 → $637 | $430.73 | +47.89% | 14 | Apr 24, 2025 | |
DHR Danaher | Reiterates: Outperform | $250 | $205.51 | +21.65% | 10 | Apr 23, 2025 | |
ILMN Illumina | Maintains: Outperform | $128 → $112 | $100.05 | +11.94% | 15 | Apr 8, 2025 | |
OABI OmniAb | Maintains: Outperform | $7 → $4 | $2.06 | +94.17% | 3 | Mar 27, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $251 | $163.36 | +53.65% | 1 | Mar 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $61 | $31.55 | +93.34% | 11 | Feb 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $13 | $2.89 | +349.83% | 6 | Nov 8, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $3.74 | +87.17% | 4 | Aug 7, 2024 |
Bio-Techne
May 8, 2025
Maintains: Sector Perform
Price Target: $72 → $63
Current: $54.41
Upside: +15.79%
Hologic
May 2, 2025
Maintains: Sector Perform
Price Target: $75 → $70
Current: $66.85
Upside: +4.71%
Bio-Rad Laboratories
May 2, 2025
Maintains: Outperform
Price Target: $409 → $392
Current: $259.88
Upside: +50.84%
Bio-Rad Laboratories
May 2, 2025
Maintains: Outperform
Price Target: $409 → $392
Current: $261.85
Upside: +49.70%
Repligen
Apr 30, 2025
Maintains: Outperform
Price Target: $202 → $189
Current: $134.00
Upside: +41.04%
Avantor
Apr 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $13.70
Upside: +45.99%
Thermo Fisher Scientific
Apr 24, 2025
Maintains: Outperform
Price Target: $651 → $637
Current: $430.73
Upside: +47.89%
Danaher
Apr 23, 2025
Reiterates: Outperform
Price Target: $250
Current: $205.51
Upside: +21.65%
Illumina
Apr 8, 2025
Maintains: Outperform
Price Target: $128 → $112
Current: $100.05
Upside: +11.94%
OmniAb
Mar 27, 2025
Maintains: Outperform
Price Target: $7 → $4
Current: $2.06
Upside: +94.17%
Mar 13, 2025
Initiates: Outperform
Price Target: $251
Current: $163.36
Upside: +53.65%
Feb 13, 2025
Maintains: Outperform
Price Target: $64 → $61
Current: $31.55
Upside: +93.34%
Nov 8, 2024
Maintains: Outperform
Price Target: $17 → $13
Current: $2.89
Upside: +349.83%
Aug 7, 2024
Maintains: Outperform
Price Target: $8 → $7
Current: $3.74
Upside: +87.17%